Professional Documents
Culture Documents
Organization Study On Ranbaxy Pharmaceuticals
Organization Study On Ranbaxy Pharmaceuticals
33
RANBAXY PHARMACEUTICALS
ACKNOWLEDGEMENT
KINSHOO SHAH
33
RANBAXY PHARMACEUTICALS
CONTENTS
1. ACKNOWLEDGEMENT
2. INTRODUCTION
3. ORGANIZATION STRUCTURE
4. SWOT ANALYSIS
5. MARKETING FUNCTION
6. HUMAN RESOURCE FUNCTION
7. FINANCE FUNCTION
8. FUTURE PLANS
9. CONCLUSION & RECOMMENDATIONS
INTRODUCTION
33
RANBAXY PHARMACEUTICALS
PHARMACEUTICAL INDUSTRY:
Pharmaceutical Industry mainly relies on the production for
drug and the use of sophisticated equipment’s this industry developed by
gradual steps from very early times from the age of dispensing pharmacy to
the large scale industry.
A pharma industry is engaged in the production, marketing
and distribution of pharmaceuticals. It may also involve in the research &
development works. In this industry FDA policies and good manufacturing
practices are followed.
33
RANBAXY PHARMACEUTICALS
RANBAXY PHARMACEUTICALS
History of Organization:
33
RANBAXY PHARMACEUTICALS
US - FDA
MHRA - UK
TGA - AUSTRALIA
MCC - SOUTH
ANVISA – BRAZIL
WHO – GENEVA
FDA – CANADA
Dewas plant of RANBAXY can be broadly divided into two
parts; one is the P’ceutical formulation & other small bulk drug plant.
33
RANBAXY PHARMACEUTICALS
COMPANY: AN OVERVIEW
HIGHLIGHTS:
Eco-friendly.
33
RANBAXY PHARMACEUTICALS
PROFILE OF PRODUCTS
33
RANBAXY PHARMACEUTICALS
Finished Drugs:
Acyclovir
Cefprozil
Cefuroxime Axetil
Cephalexin
Ciprofloxacin HCl
Clarithromycin
Fenofibrate
Fluconazole
Fosinopril Sodium
Fosinopril Sodium and Hydrochlorothiazide
Gabapentin
Ganciclovir Sodium *
Glimepiride
Isotretinoin
Lamivudine
Loratadine (OTC)
Metformin HCl
Nefazodone HCl
Nitrofurantoin; Nitrofurantoin and Macrocrystalline
Ofloxacin
Pravastatin Sodium
Ranitidine
Simvastatin
Terazosin HCl
33
RANBAXY PHARMACEUTICALS
Valacyclovir HCl
Zidovudine (PEPFAR)
Active Ingredients:
Clarithromycin
Valacyclovir HCl
Pravastatin Sodium
Acyclovir
Ciprofloxacin HCl
Ganciclovir Sodium *
Gabapentin
IMPORTANT STRATEGIES
33
RANBAXY PHARMACEUTICALS
33
RANBAXY PHARMACEUTICALS
33
RANBAXY PHARMACEUTICALS
ORGANIZATION STRUCTURE
Executive Team
The Executive Committee is an apex body at Ranbaxy that
oversees Company's global functioning. The group deliberates on important
Company issues steering it in the right direction. The Committee ensures
that all decisions are taken in the best interest of the organization. This
forum brings in different perspectives on a subject. Issues are discussed,
analyzed and concluded through exchange of ideas, reflecting the
Company's philosophy of participative management. It also facilitates the
Company's compliance with the best standards of Corporate Governance.
33
RANBAXY PHARMACEUTICALS
33
RANBAXY PHARMACEUTICALS
33
RANBAXY PHARMACEUTICALS
Overview
33
RANBAXY PHARMACEUTICALS
QUALITY ASSURANCE
This department is setup for the testing of the materials and final
products. Three types of tests are performed.
1. Chemical test
2. Physical test
3. Biological test
33
RANBAXY PHARMACEUTICALS
SWOT ANALYSIS
KEY STRENGTHS
33
RANBAXY PHARMACEUTICALS
33
RANBAXY PHARMACEUTICALS
WEAKNESS
FDA issued two warning letters to Ranbaxy and an import alert for
generic drugs produced by Ranbaxy's Dewas and Paonta Sahib plants
in India.
The letters identify the agency's concerns about deviations from US'
current Good Manufacturing Practice requirements.
33
RANBAXY PHARMACEUTICALS
OPPORTUNITIES
33
RANBAXY PHARMACEUTICALS
33
RANBAXY PHARMACEUTICALS
Ranbaxy's focus is to develop new drugs to fill the gaps and take
advantage of Ranbaxy’s strong areas.
To overcome its current challenges in cost structure and supply
chain, Ranbaxy's primary aim is to establish a management
framework that will expedite synergies. Having done that, the
company seeks to reduce its exposure to branded drugs in a way that it
can cover the impact of margin pressures on the business, especially
in Japan.
In a global pharmaceutical industry making a shift towards generics
and emerging market opportunities, acquisition of Ranbaxy signals a
move on the lines of its global counterparts Novartis and local
competitors Astellas Pharma, Eesei and Takeda Pharmaceutical.
Post acquisition challenges include managing the different working
and business cultures of the two organizations, undertaking minimal
and essential integration and retaining the management independence
of Ranbaxy without hampering synergies.
Looking ahead at 2009, apart from the on-going challenges in the US,
with the FDA as well as the abnormal rupee and global Forex
movements, Ranbaxy also has to cope with a global “depression”
scenario.
MARKETING FUNCTION
33
RANBAXY PHARMACEUTICALS
DOMESTIC MARKET:
Market share –5%.
Products portfolio contains 17 of top 300 brands Of India.
Therapeutic Width –68% of the market.
Doctors' coverage over 180 thousands.
Products distributed through 4000 stockist & 200 thousand retail
outlets.
Retail outlets coverage – 90%.
Australia
Austria
Belgium
Bangladesh
Brazil
China
Cambodia
Congo
Canada
Denmark
Dominican Republic
Egypt
Ethiopia
France
33
RANBAXY PHARMACEUTICALS
Finland
U. S. A.
U .K.
A.) ADVERTISING:
Medical Representatives are appointed to approach doctors,
druggists & chemists & publicize products.
Distribute pamphlets, calendars, diaries, notepads etc to doctors,
chemists & laboratory scientists other customers.
Display hoardings & posters.
Issue advertisements in newspapers & magazines in the favor of
public health welfare.
Produce commercial ads to be telecasted on T.V. & Radio.
B.) EVENTS:
Organize Seminars for introduction of new products.
33
RANBAXY PHARMACEUTICALS
33
RANBAXY PHARMACEUTICALS
HR VISION
HR MISSION
33
RANBAXY PHARMACEUTICALS
HR OBJECTIVES
33
RANBAXY PHARMACEUTICALS
LIFE AT RANBAXY
33
RANBAXY PHARMACEUTICALS
Salaries and other benefits in Ranbaxy are comparable with the best in
the industry and one can expect to be rewarded highly if the performance is
consistently outstanding.
Group Life Insurance, Medical Insurance and Pension plans
are a few examples of the benefits provided to the employees and their
dependents with adequate financial protection on long term basis.
STOCKOWNERSHIP
FINANCE FUNCTION
33
RANBAXY PHARMACEUTICALS
33
RANBAXY PHARMACEUTICALS
FUTURE PLANS
33
RANBAXY PHARMACEUTICALS
For the year, 2009, Ranbaxy has a clear strategy to harness its growth
potential in the emerging markets, rebuild the US business through a
series of actions on products and facilities.
33